CVS Health Corporation Company Profile (NYSE:CVS)

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc. (Omnicare) and Omnicare's long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. It operates through three segments: Pharmacy Services, Retail/LTC and Corporate. The Pharmacy Services Segment provides a range of pharmacy benefit management (PBM) solutions to its clients. As of December 31, 2016, the Retail/LTC Segment included 9,709 retail locations (of which 7,980 were its stores that operated a pharmacy and 1,674 were its pharmacies located within Target Corporation (Target) stores), its online retail pharmacy Websites, CVS.com, Navarro.com and Onofre.com.br, 38 onsite pharmacy stores, its long-term care pharmacy operations and its retail healthcare clinics.

What is CVS Health Corporation's stock symbol?

CVS Health Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVS."

How often does CVS Health Corporation pay dividends? What is the dividend yield for CVS Health Corporation?

CVS Health Corporation announced a quarterly dividend on Thursday, July 6th. Shareholders of record on Monday, July 24th will be given a dividend of $0.50 per share on Thursday, August 3rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Thursday, July 20th. View CVS Health Corporation's Dividend History.

How were CVS Health Corporation's earnings last quarter?

CVS Health Corporation (NYSE:CVS) released its quarterly earnings data on Tuesday, August, 8th. The company reported $1.33 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.31 by $0.02. The company earned $45.69 billion during the quarter, compared to analyst estimates of $45.36 billion. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.32 earnings per share. View CVS Health Corporation's Earnings History.

When will CVS Health Corporation make its next earnings announcement?

What guidance has CVS Health Corporation issued on next quarter's earnings?

CVS Health Corporation issued an update on its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $5.83-5.93 for the period, compared to the Thomson Reuters consensus estimate of $5.87. CVS Health Corporation also updated its Q3 guidance to $1.47-1.50 EPS.

Where is CVS Health Corporation's stock going? Where will CVS Health Corporation's stock price be in 2017?

What are analysts saying about CVS Health Corporation stock?

Here are some recent quotes from research analysts about CVS Health Corporation stock:

1. Guggenheim analysts commented, " Our recent meetings with CEO Larry Merlo, CFO Dave Denton, and VP-IR Nancy Christal further reinforced our confidence in 10% secular growth, which we believe the market is currently undervaluing, at a 13x P/E on somewhat depressed 2017E EPS. Bottom line, even in the face of secular gross margin erosion, in both segments, we believe the company should be able to grow EBIT by 5% on the back of a) natural growth in specialty Rx, b) increasingly rapid product innovation, c) a broadening set of productive relationships, and d) both COGS and SG&A reductions. In our view, this growth merits a valuation closer to a market multiple'we reiterate our Buy rating and $90 PT, implying 15% upside from current levels." (3/28/2017)

2. Evercore ISI analysts commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below ' dollar profit targets were unchanged in our view ' much of the delta related to where 4Q came out vs mid-point and lower inflation outlook), investors have reacted negatively to the lack of clarity on several key issues with respect to business model risk that in our minds is unlikely to dissipate until later in the year. We think management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates, but the reality is that policy noise is unlikely to dissipate and the outlook for 2018 won't start to gain clarity until the summer. We think once we get initial color on the PBM selling season, a better understanding of underlying pharmacy share shifts and profit headwinds and ultimately gain a better picture of 2018 the multiple may start to see some relief. Until then CVS shares remain inexpensive and highly leveraged to tax reform and it appears as if many years of execution are being overshadowed by a tough 18 month stretch. Given how far shares have fallen and in our view strong FCF yield support we retain our Buy rating but acknowledge the path to returns from here is likely most appropriate for those with a multi-year time horizon and a 'deep value' focus." (2/9/2017)

Who sold CVS Health Corporation stock? Who is selling CVS Health Corporation stock?

CVS Health Corporation's stock was sold by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , Arrowstreet Capital Limited Partnership, BlackRock Inc., Ameriprise Financial Inc., Pioneer Investment Management Inc., TIAA CREF Investment Management LLC, Bank of New York Mellon Corp and Alliancebernstein L.P.. Company insiders that have sold CVS Health Corporation stock in the last year include Andrew Sussman, David M Denton, Eva C Boratto, Helena Foulkes, Jonathan C Roberts and Troyen A Brennan. View Insider Buying and Selling for CVS Health Corporation.

MarketBeat's community ratings are surveys of what our community members think about CVS Health Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.